非酒精性脂肪肝 | Nonalcoholic Fatty Liver

Store/肝膽疾病 - 多學科復康 | Hepatobiliary Disease (MRP)/非酒精性脂肪肝 | Nonalcoholic Fatty Liver

非酒精性脂肪肝

隨著久坐生活方式和飲食西化在世界範圍內的傳播，非酒精性脂肪肝（NAFLD）的患病率在許多國家的兒童和老年人中都有所增加[1,2]。在美國，大約25%的成年人在沒有過量飲酒的情况下患有脂肪肝。在日本，大約三分之一的人在每年的健康檢查中被發現患有非酒精性脂肪肝[3]，估計有2000萬非酒精性脂肪肝患者。在中國，脂肪肝正以每年0.594%的速度增長，預計到2020年將有20%的中國人患上脂肪肝[4]。NAFLD正在成為世界範圍內最常見的肝病。

NAFLD常與內臟脂肪增多（肥胖）和隨後的代謝异常有關，包括胰島素抵抗、糖尿病、高血壓、血脂异常、動脈粥樣硬化和全身微炎症。最近一項涉及來自22個國家的850多萬人的薈萃分析顯示，超過80%的NASH患者超重或肥胖，72%有血脂异常，44%有2型糖尿病[13]。囙此，NAFLD也可視為代謝綜合征的肝臟表現。儘管NAFLD是葡萄糖不耐受和胰島素抵抗的原因還是結果仍存在爭議，但一項前瞻性研究表明，非糖尿病NAFLD患者發生糖尿病和心血管事件的風險高於非NAFLD患者[14]。囙此，非酒精性脂肪肝是一種有害的情况，必須採取適當的干預措施。

輕中度脂肪肝-多學科復康組合(1個月試用份量)

顯著進程:約2-3個月

多學科復康組合:

藥物及其他醫療方案,請遵醫從醫生建議
飲食營養請依營養師指引
運動及或心理輔導,請參考各專家建議
為免錯誤診斷及漏診,請上傳最近一個月醫院的專業診斷報告

不適合使用:

肝纖維化及硬化
酒精性脂肪肝
對該組合的成份有過敏
胃潰瘍

生活配合:

不能吃太飽,以8成飽肚為主
碳水化合物食物儘量減少份量
高脂、高膽固醇食物必須避開少吃
多喝白開水,每天2公升
多吃膳食纖維食物
戒掉夜宵習慣
不適宜自行補充鈣及鐵等礦物質
早睡早起,不要熬夜
每天不少於1萬步中速步行

飲食戒口:

l煎炸烤燒食物儘量少吃

l動物肝臟、血液等高鐵質食物不要吃

注意：

為營養補充品，不能代替藥物。

懷孕或哺乳期女士、嬰幼兒，請不要食用本品。

如不瞭解問題原因或問題持續，請儘快諮詢醫生。

Non-alcoholic fatty liver disease

With the worldwide spread of sedentary lifestyle and diet westernization, the prevalence of non-alcoholic fatty liver disease (NAFLD) has increased in many countries among children and the elderly alike[1,2]. Approximately 25% of adults in the United States have fatty liver in the absence of excessive ethanol consumption. In Japan, roughly a third of individuals were found to have NAFLD in annual health checkups[3], translating to an estimated 20 million NAFLD patients. In China, fatty liver disease is increasing at a rate of 0.594% per year and is expected to afflict 20% of Chinese by 2020[4]. NAFLD is becoming the most common liver disease worldwide.

NAFLD is frequently associated with increased visceral adiposity (obesity) and ensuing metabolic abnormalities, including insulin resistance, diabetes, hypertension, dyslipidemia, atherosclerosis, and systemic micro-inflammation. A recent meta-analysis involving over 8.5 million individuals from 22 countries showed that more than 80% of NASH patients were overweight or obese, 72% had dyslipidemia, and 44% had type 2 diabetes mellitus[13]. Therefore, NAFLD can also be regarded as a hepatic manifestation of metabolic syndrome. Although it remains controversial whether NAFLD is a cause or a result of glucose intolerance and insulin resistance, a prospective study has demonstrated higher risks of diabetes and cardiovascular events in non-diabetic NAFLD patients than non-NAFLD ones[14]. Therefore, NAFLD is a detrimental condition necessitating appropriate interventions.

Mild to moderate fatty liver multidisciplinary rehabilitation combination (1-month trial portion)

Significant progress: about 2-3 months

Professional rehabilitation combination:

• Please follow the doctor's advice for drugs and other medical plans

• Please follow the dietitian's guidelines for diet and nutrition

• For sports and or psychological counseling, please refer to the suggestions of experts

• To avoid misdiagnosis and missed diagnosis, please upload the professional diagnosis report of the hospital in the latest month

Not suitable for use:

Hepatic fibrosis and sclerosis
Alcoholic fatty liver
Allergic to the ingredients of the combination
Gastric ulcer

Life cooperation:

Don't eat too full, mainly 80% full belly
Try to reduce the amount of carbohydrate food
High fat and cholesterol foods must be avoided and eaten less
Drink plenty of boiled water, 2 liters a day
Eat more dietary fiber food
Get rid of the night snack habit
It is not suitable to supplement minerals such as calcium and iron
Go to bed early and get up early. Don't stay up late
No less than 10000 steps of medium speed walking every day

Dietary abstinence:

Try to eat less fried and roasted food
Do not eat high iron foods such as animal liver and blood

Be careful:

• It is a nutritional supplement and cannot replace drugs.

• Pregnant or lactating women, infants and young children, please do not eat this product.

• If you do not know the cause of the problem or the problem continues, please consult your doctor as soon as possible.

Refs:參考文獻:

An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy. Monika Rau &Andreas Geier. https://doi.org/10.1080/17512433.2021.1884068
Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol. 2019;25(2):163-177. doi:10.3748/wjg.v25.i2.163

Sort by